F. Rinaldi, M. Freeman, J. Sabbat, S. Sommer, R. Grant, J. Fujan, J. Aho
A decade ago, Yamanaka and colleagues reprogrammed cells from adult tissues into inducible pluripotent stem cells (iPSC), one of the most exciting discoveries of the 21st century. Human iPSC-derived cardiomyocytes offer enormous potential for disease modeling, high throughput toxicity screening, and use in cell-based therapies for cardiac disorders. Two years ago, we released our StemXVivo® Cardiomyocyte Differentiation Kit, which directs human pluripotent stem cells through embryonic mesoderm development to produce functional cardiomyocytes. Presently, we introduce an updated version of the kit that features more uniform differentiation and improved efficacy across different pluripotent stem cell lines. Specifically, the new StemXVivo® Cardiomyocyte Differentiation Kit generates cardiomyocytes with cell-specific marker expression and more robust and homogenous beating. The performance of the kit has been verified on human iPSCs and human embryonic stem cells (ESCs), including multiple pluripotent cell lines derived from different sources of adult somatic tissues.